Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.31 EUR | -0.76% | -2.24% | -86.56% |
Business Summary
Number of employees: 166
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Therapeutics for Rare Seizures
100.0
%
| 25 | 100.0 % | 31 | 100.0 % | +21.63% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 25 | 100.0 % | 31 | 100.0 % | +21.63% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Scott Braunstein
CEO | Chief Executive Officer | 60 | 05/18/05 |
Steven Pfanstiel
DFI | Director of Finance/CFO | 51 | 12/21/12 |
Joseph Hulihan
CTO | Chief Tech/Sci/R&D Officer | 68 | 06/19/06 |
Chief Tech/Sci/R&D Officer | - | - | |
Sonya Weigle
IRO | Public Communications Contact | - | 01/21/01 |
Christy Shafer
PRN | Corporate Officer/Principal | 48 | 10/20/10 |
General Counsel | - | - | |
Thomas Lyons
PRN | Corporate Officer/Principal | - | 01/18/01 |
Alex Aimetti
PRN | Corporate Officer/Principal | - | - |
Martha Manning
LAW | General Counsel | 69 | 15/20/15 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Tim Mayleben
BRD | Director/Board Member | 63 | 01/08/01 |
Scott Braunstein
CEO | Chief Executive Officer | 60 | 05/18/05 |
Elan Ezickson
BRD | Director/Board Member | 60 | 12/19/12 |
Seth Fischer
BRD | Director/Board Member | 68 | 06/16/06 |
Sara Nochur
BRD | Director/Board Member | 63 | 22/21/22 |
Sarah Noonberg
BRD | Director/Board Member | 56 | 16/23/16 |
Director/Board Member | 41 | 26/23/26 | |
Charles Austin
BRD | Director/Board Member | 68 | 29/20/29 |
Marvin Johnson
BRD | Director/Board Member | 61 | 18/23/18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 54,941,081 | 54,403,089 ( 99.02 %) | 7,307 ( 0.0133 %) | 99.02 % |
Company contact information
Marinus Pharmaceuticals, Inc.
5 Radnor Corporate Center 100 Matsonford Road
19087-5279, Radnor
+484 801 4670
http://www.marinuspharma.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+50.70% | 791B | |
+41.96% | 630B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 298B | |
+18.02% | 246B | |
+1.27% | 225B | |
+11.95% | 218B | |
+3.68% | 160B |
- Stock Market
- Equities
- MRNS Stock
- 61Y Stock
- Company Marinus Pharmaceuticals, Inc.